[go: up one dir, main page]

EA200800516A1 - Производные n-фенил-2-пиримидинамина и процесс их получения - Google Patents

Производные n-фенил-2-пиримидинамина и процесс их получения

Info

Publication number
EA200800516A1
EA200800516A1 EA200800516A EA200800516A EA200800516A1 EA 200800516 A1 EA200800516 A1 EA 200800516A1 EA 200800516 A EA200800516 A EA 200800516A EA 200800516 A EA200800516 A EA 200800516A EA 200800516 A1 EA200800516 A1 EA 200800516A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compound
phenyl
relates
present
Prior art date
Application number
EA200800516A
Other languages
English (en)
Other versions
EA015103B1 (ru
Inventor
Донг-Ён Ким
Дае-Жин Чо
Гонг-Ял Лии
Хонг-Ёуб Ким
Сеок-Хун Вуу
Ёнг-Сеок Ким
Сан-Эйх Лии
Бьенг-Чеол Хан
Original Assignee
Ил-Янг Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ил-Янг Фарм. Ко., Лтд. filed Critical Ил-Янг Фарм. Ко., Лтд.
Publication of EA200800516A1 publication Critical patent/EA200800516A1/ru
Publication of EA015103B1 publication Critical patent/EA015103B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Pyridine Compounds (AREA)

Abstract

Настоящее изобретение относится к новому производному N-фенил-2-пиридинамина, представленному формулой (1), и его соли, оказывающим подавляющий эффект на рак теплокровных животных, такой как рак легких, рак желудка, рак толстой кишки, рак поджелудочной железы, гепатому, рак предстательной железы, рак груди, хроническая или острая лейкемия, гематологическая злокачественная опухоль, рак головного мозга, рак мочевого пузыря, рак прямой кишки, рак шейки матки, лимфома и т.д. Настоящее изобретение также относится к способу приготовления соединения и фармацевтическому соединению для лечения вышеназванных различных заболеваний, содержащему действующее количество соединения в качестве активного ингредиента вместе с фармацевтически приемлемыми инертными носителямигде R-Rтакие, как указано выше.
EA200800516A 2005-08-05 2005-09-07 Производные n-фенил-2-пиримидинамина и способ их получения EA015103B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020050071656A KR100674813B1 (ko) 2005-08-05 2005-08-05 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
PCT/KR2005/002962 WO2007018325A1 (en) 2005-08-05 2005-09-07 N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof

Publications (2)

Publication Number Publication Date
EA200800516A1 true EA200800516A1 (ru) 2008-08-29
EA015103B1 EA015103B1 (ru) 2011-06-30

Family

ID=37727490

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800516A EA015103B1 (ru) 2005-08-05 2005-09-07 Производные n-фенил-2-пиримидинамина и способ их получения

Country Status (16)

Country Link
US (1) US7501424B2 (ru)
EP (1) EP1922309B1 (ru)
JP (1) JP5094721B2 (ru)
KR (1) KR100674813B1 (ru)
CN (1) CN101155786B (ru)
AU (1) AU2005335298C1 (ru)
CA (1) CA2617991C (ru)
DK (1) DK1922309T3 (ru)
EA (1) EA015103B1 (ru)
ES (1) ES2493627T3 (ru)
MX (1) MX2008001221A (ru)
NZ (1) NZ564908A (ru)
PL (1) PL1922309T3 (ru)
PT (1) PT1922309E (ru)
RS (1) RS53379B (ru)
WO (1) WO2007018325A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100654039B1 (ko) 2005-11-14 2006-12-05 에스케이 텔레콤주식회사 무선 인터넷에서 서비스 서버의 인증방법 및 이를 이용한결제방법
AU2007309427B2 (en) 2006-10-23 2013-02-28 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
RU2009120882A (ru) * 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
KR101122481B1 (ko) * 2007-05-04 2012-02-29 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물
US8338417B2 (en) * 2007-05-04 2012-12-25 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
BRPI0815572A2 (pt) 2007-08-22 2015-02-18 Irm Llc Compostos e composições como inibidores de quinases
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
RU2486180C1 (ru) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Способ получения 2-ариламино-4-гетарилпиримидинов
KR101956586B1 (ko) * 2012-03-27 2019-03-11 일양약품주식회사 약제학적 조성물 및 이의 제조방법
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN104940748A (zh) * 2015-06-09 2015-09-30 林正兴 一种治疗胃癌的药物组合物
US11091466B2 (en) 2017-03-17 2021-08-17 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9
CN107056713A (zh) * 2017-05-18 2017-08-18 厦门大学 4‑((4‑取代芳基‑2‑嘧啶基)氨基)苯甲酰肼衍生物及其制备方法和应用
CN111039932B (zh) * 2019-12-13 2023-09-12 安徽峆一药业股份有限公司 一种拉多替尼的高收率合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO2000069283A1 (en) * 1999-05-13 2000-11-23 The Nutrasweet Company USE OF ADDITIVES TO MODIFY THE TASTE CHARACTERISTICS OF N-NEOHEXYL-α-ASPARTYL-L-PHENYLALANINE METHYL ESTER
BR0014454A (pt) * 1999-10-04 2002-08-20 Composição edulcorante com um alto grau de edulcoração, edulcorante, alimento e bebida, ou um outro produto edulcorado, processos para conferir um sabor doce, e para corrigir um sabor, modificador de sabor, e, alimento e bebida, um medicamento etc. com sabor amargo aperfeiçoado
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
CA2446756C (en) * 2001-06-01 2011-03-08 Vertex Pharmaceuticals Incorporated Thiazole compounds useful as inhibitors of protein kinase
US6958340B2 (en) * 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US7494997B2 (en) * 2002-06-28 2009-02-24 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1605946B1 (en) * 2003-03-25 2008-05-28 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
AU2004225965A1 (en) * 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2006527230A (ja) * 2003-06-13 2006-11-30 ノバルティス アクチエンゲゼルシャフト Ｒａｆキナーゼ阻害剤としての２−アミノピリミジン誘導体
JPWO2005063720A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
MXPA06007237A (es) * 2003-12-25 2006-08-18 Nippon Shinyaku Co Ltd Derivado de amida y medicamento que lo contiene.
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途

Also Published As

Publication number Publication date
EP1922309A1 (en) 2008-05-21
RS53379B (sr) 2014-10-31
US20080096899A1 (en) 2008-04-24
ES2493627T3 (es) 2014-09-12
CA2617991C (en) 2011-08-09
NZ564908A (en) 2011-02-25
KR100674813B1 (ko) 2007-01-29
PT1922309E (pt) 2014-09-02
JP5094721B2 (ja) 2012-12-12
AU2005335298B2 (en) 2010-05-27
PL1922309T3 (pl) 2014-11-28
EP1922309A4 (en) 2009-10-14
EA015103B1 (ru) 2011-06-30
AU2005335298A1 (en) 2007-02-15
DK1922309T3 (da) 2014-08-25
MX2008001221A (es) 2009-02-24
JP2009503060A (ja) 2009-01-29
CA2617991A1 (en) 2007-02-15
CN101155786B (zh) 2012-08-29
CN101155786A (zh) 2008-04-02
WO2007018325A1 (en) 2007-02-15
EP1922309B1 (en) 2014-05-21
AU2005335298C1 (en) 2010-11-25
RS20080002A (sr) 2009-07-15
US7501424B2 (en) 2009-03-10

Similar Documents

Publication Publication Date Title
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
US20250120947A1 (en) Compounds and methods to sensitize cancer cells to cisplatin
IL278297B1 (en) Transmutable heterocyclic ptpn11 inhibitors
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
PH12021552482A1 (en) Compounds targeting prmt5
JP2008535902A5 (ru)
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
MX2012001420A (es) Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus.
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA200000847A1 (ru) Противоопухолевые средства
US9481678B2 (en) Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors
EA201892460A1 (ru) Производные аденина как ингибиторы протеинкиназ
PH12021552953A1 (en) Tricyclic compounds
RU2016149761A (ru) Производные нуклеозидов для лечения ракового заболевания
TNSN05223A1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
EP2970310A1 (en) 5-bromo-indirubins
Pansare et al. A facile synthesis of novel series (Z)-2-((4-oxo-5-(thiophen-2-ylmethylene)-4, 5-dihydrothiazol-2-yl) amino) substituted acid
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
SI1727817T1 (sl) Azabiciklooktan-3-onski derivati in njihova uporaba
JP2010535204A5 (ru)
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.
PH12022550050A1 (en) Camptothecin derivatives with a disulfide moiety and a piperazine moiety
EA200970848A1 (ru) Амидосодержащие соединения и их применение в качестве противоопухолевых агентов
AU2006246204B2 (en) Antineoplastic compounds and pharmaceutical compositions thereof
WO2014060366A1 (fr) Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY MD TM

QB4A Registration of a licence in a contracting state